查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1179900

2023-2030 年全球電氣診斷設備市場

Global Electro-Diagnostic Devices Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

電診斷是一種測試技術，可以估計體內電活動的速率和範圍。 電診斷儀器檢查肌肉和神經衝動的電傳導和活動。 這些設備可幫助從業者和醫生為患有肌病、神經病、神經肌肉接頭疾病、神經叢病等的患者推薦診斷。 常見的電學診斷包括神經傳導研究 (NCS)、體感誘發電位研究 (SSEP) 和肌電圖 (EMG)。

市場動態

在預測期內，產品推出的增加、老年人口的增加以及相關的慢性病正在推動全球電診斷設備市場的增長。

不斷增加的產品介紹正在推動市場的增長。

在預測期內，不斷增長的市場發展、不斷增加的老年人口和慢性病正在推動全球電診斷設備市場的增長。 例如 2020 年 9 月，美國 FDA 批准的個人心電圖 (ECG) 技術公司 AliveCor 今天推出了經過臨床驗證的個人心電圖設備 KardiaMobile 6L。以全球唯一的 6 進入印度市場-鉛，FDA 批准的個人 ECG 設備能夠檢測 3 種最常見的心律失常類型，心房顫動 (AFib)、心動過緩和心動過速。 由於這些疾病需要定期監測，因此患者可以在家中自行檢測這些心律失常。 KardiaMobile 6L 可以在短短 30 秒內記錄醫療心電圖。 此外，2022 年 10 月，印度第一家非接觸式遠程患者監護 (RPM) 公司 Dozee 將宣布推出門診心電圖 (ECG) 貼片，以監測心血管疾病 (CVD) 患者的情況。

此外，2020 年 7 月，提供神經病學、AI 和機器學習等腦相關產品和解決方案的醫療設備和技術公司 Brain Scientific 推出了一款名為“Neuro Cap”的一次性腦電耳機，該耳機經過改進和添加了新功能。 同樣，2022年1月，Cadwell在美國推出了“陰部（骨盆底）刺激記錄電極和電纜”。 Spethmedica 製造的陰蒂電極與 Sierra Summit 系統一起開發，用於評估肛門括約肌的陰蒂神經末梢潛伏期 (PNTML)。 因此，上述數據表明，在預測期內，增加產品引進將提振全球電氣診斷設備市場。

設備的高成本預計會阻礙全球電氣診斷設備市場的增長。

然而，阻礙市場增長的關鍵因素之一是安裝和維護電氣診斷設備的高成本。 例如，手持式心電圖機的價格為 500 美元，筆記本電腦式心電圖機的價格約為 1000-2000 美元。 同時，動態心電圖設備的平均成本為 1000 到 3000 美元。

COVID-19 的影響。

COVID-19 大流行對全球電氣診斷設備市場產生了一定程度的影響。 在大流行初期，由於對 COVID-19 的高度關注，大多數診斷程序被取消或推遲。 然而，隨著 COVID-19 病例的減少，電診斷程序已成為一種更加謹慎的做法。 例如，2020 年初，美國確認停止選擇性醫療程序，包括非緊急門診和住院電診斷 (EDx) 測試。 此後，EDx 實驗室在美國神經肌肉和電診斷醫學學會 (AANEM) 的指導下重新開放，儘管某些地區每天的新病例數有所下降。 此外，COVID-19 還帶動了個人監控設備的發展，對市場產生了積極影響。 因此，可以說，COVID-19對全球電診斷設備市場產生了多方面的影響。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

  • 市場影響因素
    • 司機
      • 增加產品發布
      • 慢性病增加
    • 約束因素
      • 設備成本高
    • 商機
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按產品類型

  • 心電圖 (ECG)
  • 肌電圖 (EMG)
  • 腦電圖 (EEG)
  • 神經傳導研究 (NCS)
  • 視網膜電圖 (ERG)
  • 胃電圖 (EGG)

第 8 章產品流動性

  • 固定式
  • 便攜式

第 9 章最終用戶

  • 醫院和診所
  • 門診手術中心 (ASC)
  • 家庭護理
  • 診斷中心

第10章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第11章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準

第12章公司簡介

  • GE Healthcare
    • 公司簡介
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Medtronic
  • Abbott
  • Boston Scientific
  • Bionet America, Inc.
  • Philips Healthcare
  • Cardinal Health
  • B. Braun Melsungen AG
  • Stryker Corporation
  • Becton, Dickinson and Company

第13章數據M

簡介目錄
Product Code: DMMD6130

Market Overview

The global electro-diagnostic devices market size was valued at US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period (2023-2030).

Electro-diagnostics is a testing technique that estimates the body's speed or extent of electrical activity. Electro-diagnostics equipment examines muscle and nerve impulses' electrical conduction or activity. These devices help practitioners or physicians recommend diagnoses for patients such as myopathy, neuropathy, neuromuscular junction disorder, and plexopathy. The major electro-diagnostic study includes nerve conduction studies (NCS), somatosensory evoked potential studies (SSEPs), and electromyography (EMG).

Market Dynamics

The rising product introductions, growing geriatric population and associated chronic diseases are boosting the global electro-diagnostic devices market growth in the forecast period.

The increasing product launches are fueling growth in the market.

The increased market developments, growing geriatric population and chronic diseases are boosting the global Electro-Diagnostic Devices market growth in the forecast period. For instance, in September 2020, AliveCor, a US FDA-approved personal electrocardiogram (ECG) technology firm, today entered the Indian market with the introduction of its clinically-validated personal ECG device, KardiaMobile 6L, the world's only six-lead, FDA-cleared personal ECG device and can detect three most common arrhythmias, the atrial fibrillation (AFib), bradycardia, and tachycardia. Since these conditions require regular monitoring, the patients can test themselves for these arrhythmias at home. The KardiaMobile 6L can record a medical-grade ECG in only 30 seconds. Also, in October 2022, Dozee, India's first contactless remote patient monitoring (RPM) company, declared about launching an ambulatory electrocardiogram (ECG) patch to monitor cardiovascular disease (CVD) patients.

Moreover, in July 2020, Brain Scientific Inc., a medical device and technology company delivering products and solutions associated with the brain, including neurology, AI and machine learning, improved its disposable EEG headset, NeuroCap, with new features. Likewise, in January 2022, Cadwell launched the Pudendal (Pelvic Floor) Stimulating and Recording Electrode and Cable in the United States. The pudendal electrode, fabricated by Spes Medica, is developed with the Sierra Summit system to assess pudendal nerve terminal motor latency (PNTML) in the anal sphincter. Therefore, the data above indicates that the increased product introductions boost the global electro-diagnostic devices market during the forecasted period.

The high cost of the equipment is expected to hamper global electro-diagnostic devices market growth.

However, one of the important factors hampering the market growth is the high setup and upkeep costs of electro-diagnostic devices. For instance, handheld ECG machines can be $500, and laptop-based ECG machines cost about $1000-$2,000. At the same time, portable ECG machines cost between $1,000-$3,000 on average.

COVID-19 Impact.

The COVID-19 pandemic moderately impacted the global electro-diagnostic devices market. Most diagnostics procedures were canceled or postponed during the early pandemic day since the major focus was on COVID-19. Still, later with the decrease in cases of COVID-19, electro-diagnosis procedures were performed with extreme precautions. For instance, in early 2020, the cancellation of elective medical procedures in the United States, including non-urgent outpatient and inpatient electro-diagnostic (EDx) studies, was observed. While certain regions subsequently showed a decrease in daily new cases, EDx laboratories were reopened under the direction of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM). Furthermore, COVID-19 led to the development of personalized monitoring devices which positively impacted the market. Therefore, from the data mentioned, COVID-19 had a mixed impact on the global electro-diagnostic devices market.

Segment Analysis

Electrocardiography (ECG) devices are expected to dominate the electro-diagnostic devices market throughout the forecast period (2022-2029).

Electrocardiography (ECG) product is estimated to hold most of the market share throughout the forecast period. The growing cases of cardiovascular diseases worldwide ensure that the electrocardiography (ECG) devices segment grows at a high CAGR during the forecast period. For instance, according to the WHO, cardiovascular diseases (CVDs) are the major cause of death globally, taking over 17.9 million lives annually. Over 75% of CVD-related deaths happen in low- and middle-income countries. The World Heart Federation forecasts over 23 million CVD-related deaths annually by 2030.

Furthermore, the increased initiatives by various entities to spread awareness about cardiac health are boosting segment growth in the forecasted period. For example, NHLBI, The Heart Truth, and organizations around the United States on National Wear Red Day marked each year on the first Friday in February to obtain greater awareness of heart disease as a leading cause of death for Americans. Also, on February 10, 2019, the Heart Foundation introduced the coordinated advertising and editorial 'Serial Killer' campaign in collaboration with News Corp Australia to point out to Australians that heart disease is the nation's leading cause of death. The campaign delivered Australians with an easy-to-use online tool, the Heart Age Calculator, to enable them to evaluate their own risk for heart disease and called on the Government to support the prevention of heart disease by supplying a Medicare advantage for Heart Health Checks.

Additionally, CDC run Million Hearts is a national endeavor to avert 1 million heart attacks and strokes in the period of five years. It concentrates on enforcing a small set of evidence-based preferences and targets that can enhance cardiovascular health for all. Therefore, from the mentioned data, it is estimated that the electrocardiography (ECG) devices segment will grow at a high CAGR throughout the forecast period.

Geographical Analysis

North America holds the largest market share of global electro-diagnostic devices.

North America is anticipated to hold most of the global electro-diagnostic devices market during the forecasted period (2022-2029) because of the increasing number of developed and well-staffed hospitals and increased healthcare expenditure in this region. For instance, according to the American Hospital Association, currently, over 6,093 hospitals have more than 920,531 staff bed capacity, which in 2022 had over 33,356,853 admissions generating $ 1,213,881,001,000 of expenditure. In addition, the growing geriatric population and related chronic disease cases in this region contribute to the region's dominance over the global electro-diagnostic device market. For example, according to the United States Census Bureau, over 54 million adults ages 65 and older living in the United States in 2021, accounting for around 16.5% of the nation's population. The number of older U.S. adults is growing. By 2050, the total number of adults ages 65 and older is projected to reach 85.7 million, making up around 20% of the overall U.S. population.

Furthermore, according to the CDC, six out of ten U.S. adults have at least one chronic disease. Moreover, according to the same source, approximately 697,000 people in the United States died from heart disease in 2020. The American Heart Association estimated that By 2035 over 130 million U.S. adults will have some heart disease. Thus, the mentioned data indicates that North America will dominate the global electro-diagnostic devices market in the forecast period.

Competitive Landscape

The global electro-diagnostic devices market is fairly consolidated, with selected key players accounting for the predominant market share. The major players with significant market share include Stryker Corporation, Becton, Dickinson and Company, Boston Scientific, Medtronic, Abbot, Bionet America, Inc., Philips Healthcare, Cardinal Health, GE Healthcare, and B. Braun Melsungen AG, among others. The key players focus on R&D, product innovation, and product outreach through distribution through local suppliers and distributors worldwide. For instance, in November 2022, Bionet America, Inc. announced its plan to restructure its diagnostics division to make around 300 million euros in savings by 2025.

GE Healthcare

Overview:

GE Healthcare is headquartered in Chicago, Illinois, United States, and was founded in 2004. It is a subsidiary of the American Multinational Conglomerate General Electric. It is a leading manufacturer and distributor of diagnostic imaging and radiopharmaceuticals for imaging modalities used in medical imaging procedures.

Product Portfolio:

GE Healthcare's product portfolio of electro-diagnostic devices has CARESCAPE B450 Monitor: The CARESCAPE B450 monitor functions seamlessly with the CARESCAPE ONE monitor or CARESCAPE Patient Data Module (PDM) and one additional e-module, delivering the ability to monitor patients with various insights. Portable and inexpensive, it's developed with emergency departments, surgery centers, and step-down units in mind.

The global electro-diagnostic devices market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Product Launches
      • 4.1.1.2. Growing Prevalence of Chronic Diseases
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of devices
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Electrocardiography (ECG)
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Electromyogram (EMG)
  • 7.4. Electroencephalography (EEG)
  • 7.5. Nerve Conduction (NCS)
  • 7.6. Electroretinography (ERG)
  • 7.7. Electrogastrography (EGG)

8. By Product Mobility

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Mobility
    • 8.1.2. Market Attractiveness Index, By Product Mobility
  • 8.2. Stationary
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Portable

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals and Clinics
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Ambulatory Surgical Centers (ASCs)
  • 9.4. Homecare
  • 9.5. Diagnostic Centers

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Mobility
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Mobility
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Mobility
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Mobility
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Mobility
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. GE Healthcare
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Medtronic
  • 12.3. Abbott
  • 12.4. Boston Scientific
  • 12.5. Bionet America, Inc.
  • 12.6. Philips Healthcare
  • 12.7. Cardinal Health
  • 12.8. B. Braun Melsungen AG
  • 12.9. Stryker Corporation
  • 12.10. Becton, Dickinson and Company

LIST NOT EXHAUSTIVE

13. DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us